December 2025, Vol 2, No 11
The federal government shutdown has once again highlighted critical challenges in healthcare access for veterans, particularly those living in underserved areas. Read More ›
By Janette Merrill, DHA CHES; Margaret Hammersla, PhD, ANP-BC; Lyndee Fogel, PharmD, AC-E; Sarah Adsit, PA, MS; Meghan Gunn, MA; Marcie Squirewell Wright, PhD, MPH; Robert A. Winn, MD
In Montana’s 147,000 square miles of frontier, geography isn’t just a backdrop, it’s a defining force that shapes healthcare access and outcomes. Read More ›
On November 6, 2025, the FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for adults with high-risk smoldering multiple myeloma (SMM). Read More ›
On October 23, 2025, the FDA approved belanta-mab mafodotin-blmf (Blenrep) in combination with bortezomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma. Read More ›
On October 24, 2025, the FDA approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 years and older with relapsed or refractory acute myeloid leukemia (AML) characterized by a susceptible nucleophosmin 1 (NPM1) mutation with no satisfactory alternative treatment options. Read More ›
Lung cancer remains the leading cause of cancer-related death worldwide, but advances in molecular biology have transformed treatment from a one-size-fits-all approach to one guided by precision medicine. Read More ›